Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Reconstitute at 0.2 mg/mL in sterile PBS.
Pro-caspase 10 is the inactive precursor form of caspase 10, an important enzyme in the family of cysteine-aspartic proteases (caspases) involved in the regulation of apoptosis, or programmed cell death. Caspase 10 is primarily activated through the extrinsic apoptosis pathway, which is triggered by the binding of death ligands, such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), to their respective death receptors on the cell surface. Upon activation, pro-caspase 10 is cleaved into its active form, which then initiates a cascade of proteolytic events leading to cell death. This process is crucial for maintaining cellular homeostasis, eliminating damaged or infected cells, and regulating immune responses. Dysregulation of caspase 10 activity can contribute to various pathological conditions, including cancer, autoimmune diseases, and neurodegenerative disorders. For instance, mutations or alterations in the expression of pro-caspase 10 can lead to impaired apoptosis, allowing cancer cells to evade cell death and proliferate uncontrollably. Understanding the regulation, activation, and function of pro-caspase 10 is essential for developing therapeutic strategies aimed at modulating apoptosis in disease contexts. Research into pro-caspase 10 provides valuable insights into the mechanisms of cell death and the potential for targeting apoptotic pathways in the treatment of cancer and other diseases.
仅用于科研。不用于诊断过程。未经明确授权不得转售。